Intravenous acetylcysteine for the treatment of acetaminophen overdose

Wendy Klein-Schwartz, Suzanne Doyon

Research output: Contribution to journalArticle

Abstract

Importance of the field: Acetaminophen is a leading cause of overdose-related hepatotoxicity. Although acetylcysteine prevents or minimizes acetaminophen-induced hepatotoxicity and reduces mortality, some patients presenting with complicated overdose scenarios (massive ingestions or combination or modified-release formulations) may develop toxicity despite administration of recommended dosage regimen. Areas covered in this review: The article evaluates evidence regarding intravenous acetylcysteine's effectiveness in patients with acute overdoses who receive treatment within 10 h or > 10 h, patients with chronic supratherapeutic ingestions, and those with acetaminophen-induced fulminant hepatic failure. Intravenous and oral acetylcysteine are compared. What the reader will gain: A one-size-fits-all approach towards acetylcysteine therapy provides suboptimal care in some patients. High-risk patients are identified. Specific discontinuation criteria are presented. Take home message: The standard intravenous regimen will effectively treat most early-presenting uncomplicated overdoses. Acetylcysteine dosing should be individualized in patients with complicated presentations and in particular situations in which plasma acetaminophen concentrations may be persistently elevated at the end of the infusion or in late presenters. More studies are needed to evaluate the optimal intravenous dosage regimen and the role of oral acetylcysteine in these high-risk patients. Treatment decisions may be aided by consultation with a poison center and/or clinical toxicologist.

Original languageEnglish (US)
Pages (from-to)119-130
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Fingerprint

Acetylcysteine
Acetaminophen
Therapeutics
Eating
Acute Liver Failure
Poisons
Referral and Consultation
Mortality

Keywords

  • Acetaminophen overdose
  • Acetaminophen poisoning
  • Acetylcysteine
  • Hepatotoxicity
  • Paracetamol

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Intravenous acetylcysteine for the treatment of acetaminophen overdose. / Klein-Schwartz, Wendy; Doyon, Suzanne.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 1, 01.2011, p. 119-130.

Research output: Contribution to journalArticle

Klein-Schwartz, Wendy ; Doyon, Suzanne. / Intravenous acetylcysteine for the treatment of acetaminophen overdose. In: Expert Opinion on Pharmacotherapy. 2011 ; Vol. 12, No. 1. pp. 119-130.
@article{ed7abbbd7adb48fc808837146c458385,
title = "Intravenous acetylcysteine for the treatment of acetaminophen overdose",
abstract = "Importance of the field: Acetaminophen is a leading cause of overdose-related hepatotoxicity. Although acetylcysteine prevents or minimizes acetaminophen-induced hepatotoxicity and reduces mortality, some patients presenting with complicated overdose scenarios (massive ingestions or combination or modified-release formulations) may develop toxicity despite administration of recommended dosage regimen. Areas covered in this review: The article evaluates evidence regarding intravenous acetylcysteine's effectiveness in patients with acute overdoses who receive treatment within 10 h or > 10 h, patients with chronic supratherapeutic ingestions, and those with acetaminophen-induced fulminant hepatic failure. Intravenous and oral acetylcysteine are compared. What the reader will gain: A one-size-fits-all approach towards acetylcysteine therapy provides suboptimal care in some patients. High-risk patients are identified. Specific discontinuation criteria are presented. Take home message: The standard intravenous regimen will effectively treat most early-presenting uncomplicated overdoses. Acetylcysteine dosing should be individualized in patients with complicated presentations and in particular situations in which plasma acetaminophen concentrations may be persistently elevated at the end of the infusion or in late presenters. More studies are needed to evaluate the optimal intravenous dosage regimen and the role of oral acetylcysteine in these high-risk patients. Treatment decisions may be aided by consultation with a poison center and/or clinical toxicologist.",
keywords = "Acetaminophen overdose, Acetaminophen poisoning, Acetylcysteine, Hepatotoxicity, Paracetamol",
author = "Wendy Klein-Schwartz and Suzanne Doyon",
year = "2011",
month = "1",
doi = "10.1517/14656566.2011.537261",
language = "English (US)",
volume = "12",
pages = "119--130",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Intravenous acetylcysteine for the treatment of acetaminophen overdose

AU - Klein-Schwartz, Wendy

AU - Doyon, Suzanne

PY - 2011/1

Y1 - 2011/1

N2 - Importance of the field: Acetaminophen is a leading cause of overdose-related hepatotoxicity. Although acetylcysteine prevents or minimizes acetaminophen-induced hepatotoxicity and reduces mortality, some patients presenting with complicated overdose scenarios (massive ingestions or combination or modified-release formulations) may develop toxicity despite administration of recommended dosage regimen. Areas covered in this review: The article evaluates evidence regarding intravenous acetylcysteine's effectiveness in patients with acute overdoses who receive treatment within 10 h or > 10 h, patients with chronic supratherapeutic ingestions, and those with acetaminophen-induced fulminant hepatic failure. Intravenous and oral acetylcysteine are compared. What the reader will gain: A one-size-fits-all approach towards acetylcysteine therapy provides suboptimal care in some patients. High-risk patients are identified. Specific discontinuation criteria are presented. Take home message: The standard intravenous regimen will effectively treat most early-presenting uncomplicated overdoses. Acetylcysteine dosing should be individualized in patients with complicated presentations and in particular situations in which plasma acetaminophen concentrations may be persistently elevated at the end of the infusion or in late presenters. More studies are needed to evaluate the optimal intravenous dosage regimen and the role of oral acetylcysteine in these high-risk patients. Treatment decisions may be aided by consultation with a poison center and/or clinical toxicologist.

AB - Importance of the field: Acetaminophen is a leading cause of overdose-related hepatotoxicity. Although acetylcysteine prevents or minimizes acetaminophen-induced hepatotoxicity and reduces mortality, some patients presenting with complicated overdose scenarios (massive ingestions or combination or modified-release formulations) may develop toxicity despite administration of recommended dosage regimen. Areas covered in this review: The article evaluates evidence regarding intravenous acetylcysteine's effectiveness in patients with acute overdoses who receive treatment within 10 h or > 10 h, patients with chronic supratherapeutic ingestions, and those with acetaminophen-induced fulminant hepatic failure. Intravenous and oral acetylcysteine are compared. What the reader will gain: A one-size-fits-all approach towards acetylcysteine therapy provides suboptimal care in some patients. High-risk patients are identified. Specific discontinuation criteria are presented. Take home message: The standard intravenous regimen will effectively treat most early-presenting uncomplicated overdoses. Acetylcysteine dosing should be individualized in patients with complicated presentations and in particular situations in which plasma acetaminophen concentrations may be persistently elevated at the end of the infusion or in late presenters. More studies are needed to evaluate the optimal intravenous dosage regimen and the role of oral acetylcysteine in these high-risk patients. Treatment decisions may be aided by consultation with a poison center and/or clinical toxicologist.

KW - Acetaminophen overdose

KW - Acetaminophen poisoning

KW - Acetylcysteine

KW - Hepatotoxicity

KW - Paracetamol

UR - http://www.scopus.com/inward/record.url?scp=78650473770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650473770&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.537261

DO - 10.1517/14656566.2011.537261

M3 - Article

C2 - 21126198

AN - SCOPUS:78650473770

VL - 12

SP - 119

EP - 130

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -